FDA Chief Seeks Federal Probe Into Approval of Alzheimer’s Drug

Published on July 9, 2021

A top official at the U.S. drug regulator on Friday called for a federal probe into the interactions between the agency’s representatives and Biogen Inc that led to the approval of the company’s Alzheimer’s disease drug last month. Janet Woodcock, acting commissioner of the…

Read Full Article (External Site)